Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SNSP 113

Next Previous
X
Search
Drug Profile

SNSP 113

Alternative Names: MIIST-113; PAAG-15A; SNSP113; SYGN113

Latest Information Update: 11 Apr 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Synedgen
  • Developer Anagram Therapeutics; Synedgen
  • Class Anti-inflammatories; Antibacterials; Antifibrotics; Polymers; Polysaccharides
  • Mechanism of Action Cell adhesion molecule inhibitors; Cell wall modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cystic fibrosis; Lung disorders
  • No development reported Staphylococcal infections

Most Recent Events

  • 04 Apr 2023 Synspira is now called Anagram Therapeutics
  • 22 Mar 2022 Synspira Therapeutics completes a phase-II clinical trial in Cystic fibrosis in Hungary (Inhalation) (EudraCT2019-003178-25)
  • 28 Feb 2022 No recent reports of development identified for preclinical development in Staphylococcal-infections in USA (Inhalation)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top